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Abstract 
We have purified a serine proteinase from the membrane of U-937 cells that was inhibited in a tight-binding manner by recombinant gp120 and 
by peptides mimicking the V3 loop of gp120 [(1993) FEBS Lett. 317, 167-1721. This proteinase has now been characterized, both structurally and 
functionally. It has a dual trypsin- and chymotrypsin-like specificity, and N-terminal sequence analysis of the iirst 32 residues indicates complete 
identity with leukocyte cathepsin G. Cathepsin G-like material was located at the surface of U-937 cells using a monoclonal antibody directed against 
leukocyte cathepsin G, and polyclonal anti-cathepsin G antibodies precipitated the purified proteinase. However, the U-937 enzyme differs slightly 
from commercial leukocyte cathepsin G in its apparent M, because of different glycosylation. No other protein structurally related to cathepsin G 
was found upon screening a U-937 cDNA library using several oligonucleotide probes constructed from the membrane proteinase N-terminal amino 
acid sequence. The possible interaction of a cathepsin G-like proteinase at the surface of U-937 cells with the V3 loop of HIV-l gp120 is discussed. 
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1. Introduction 
The binding of the gp120 envelope glycoprotein of 
HIV-l to the CD4 receptor of permissive cells does not 
seem to be sufficient to allow virus entry. The possibility 
that additional components at the surface of host cells 
are required for cell infection has been widely discussed 
[l-5]. The identity of these components is not yet known, 
but they might be cell-specific and also differ from spe- 
cies to species [6,7]. It has been suggested that one of 
these cofactors could be a proteolytic enzyme, because 
a conserved region at the crown of the V3 loop is similar 
to Kunitz-type proteinase inhibitors [8]. A membrane- 
associated proteinase that interacts with the V3 loop of 
HIV-l gp120 was first identified on the CD4+ T lympho- 
cyte membrane by Hattori et al. [9,10]. Since then, other 
membrane proteinases that interact with the V3 loop or 
may be involved in HIV infection have been described 
at the surface of HIV-sensitive cell lines [S-13]; the most 
recently reported is dipeptidyl peptidase IV [14]. Shultz 
et al. [15] have suggested that cell surface proteinases 
cleave gp120, allowing a change in conformation neces- 
sary for virus-host ceil fusion. Several sites within the V3 
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Abbreviations: ABTS, 2,2’-azino-bis (3-ethylbenzthiazolin~6-sulfonic 
acid); DTNB, (5,5’-dithiobis-(2nitrobenzoic acid); NaCl&, phos- 
phate-buffered saline; PCR, polymerase chain reaction; STI, soybean 
trypsin inhibitor; Sue-Ala-Ala-Pro-Phe-SBzl, N-cc-Cbz-alanyl-alanyl- 
prolyl-pheuylalanyl-thiobenzylester . HCI, TFA, trifluoroacetic acid; 
Z-Lys-SBzl, N-cc-Cbz-L-Lysine-thiobenzylester . HCl. 
loop of different HIV strains that could be cleaved by 
trypsin-like, chymotrypsin-like and aspartyl proteinases 
have been identified [ 161, but no proof has been provided 
that gp120 is actually cleaved during infection. It could 
be that the simple binding of gp120 to the surface pro- 
teinase via its V3 loop, without subsequent cleavage, is 
sufficient for correct exposure of the virus, fusion, and 
entry into the cell. Whether or not the cleavage of the V3 
loop is required in the process, the proteinase that may 
be involved should have a rather wide specificity if one 
takes into account the variability of V3 sequences among 
infectious HIV isolates [ 151. Interestingly, tryptase TL-2 
has both trypsin-like and chymotrypsin-like specificities, 
which satisfy this requirement [9]. Small changes in the 
amino acid sequence of the V3 loop can result in dra- 
matic changes in cell tropism, cytopathogenicity and in- 
fection [4,17,18]. This is consistent with the role of a 
proteinase as a cofactor, the specificity of which may be 
abolished by a single amino acid substitution at a critical 
position in the substrate [19]. 
We have previously shown that a membrane-associ- 
ated serine proteinase from U-937 cells interacts and is 
specifically inhibited by recombinant gp120 from HIV-l 
and by synthetic peptides spanning the V3 loop [13]. 
However, the small amount of material obtained after 
the last step of purification was not sufficient for its 
complete physicochemical characterization or subse- 
quent investigation of its potential role in HIV infection. 
This report further describes the physicochemistry and 
function of the proteinase. The results are discussed in 
terms of its possible involvement in infection by HIV 
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2. Materials and methods 
2.1. PuriJication and identification of a membrane-associated serine 
proteinase from U-937 monocytes 
Cells from the human promonocyte cell line U-937 [20] were cultured 
as described earlier [ 131. Briefly about 2.10”’ cells were resuspended in 
relax buffer (10 mM piperaxine-N-llr-bis(2-ethane sulfonic acid) HCl, 
uH 6.8, 3.5 mM M&l,. 0.1 M KCl. 1.25 mM ethvlenediamine- 
ietraacetic acid) and disrupted by N2 cavitation. The r&lting lysate 
was centrifuged at 5,000 x g (20 min, 4°C) to eliminate nuclei and intact 
cells. Granules and mitochondria were pelleted by centrifugation at 
45,000 x g for 13 min at 4°C. Finally, membranes were isolated by 
ultracentrifugation (100,000 x g, 60 min, 4°C) and their purity checked 
by electron microscopy. The membrane pellet was extracted twice by 
sonication and centrifuged (25,006 x g, 20 min, 4°C). Supematants 
were layered on agarose-immobilixed benzamidine and eluted as in [ 131. 
The following steps of chromatography on hydroxyapatite and Super- 
ose 12 remained unchanged. All the fractions eluted from the Superose 
12 column were assayed for esterolytic activity using Z-Lys-SBxl and 
Sue-Ala-Ala-Pro-Phe-SBxl as substrates. Enxymatically active fractions 
were pooled, concentrated, titrated with ST1 and stored at -70°C in 5 
mM sodium phosphate buffer, 2 M NaCl, pH 6.2. 
2.2. Enzyme assays 
The chromogenic substrates Z-Lys-SBxl and Suc-Ala-Ala-Pro-Phe- 
SBxl were assayed under standardized conditions [ 13,21,22]. Kinetic 
parameters were determined by varying the amount of substrate (0.25- 
I. 125 mM) and using the Hanes linear plot (S/v vs. 5’) 1231. The muitied 
membrane proteina& was titrated with STI, prepared as a 3.5 -lo-’ M 
stock solution in 0.1 M Tris-HCl buffer, pH 8.2 [24]. Purified enzyme 
(5 ~1) was incubated with inhibitor (cl .2.10-* M 6nal concentration) 
for 15 min at 25°C before starting the reaction with Z-Lys-SBxl or 
Sue-Ala-Ala-Pro-Phe-SBzl (0.37 mM final). Substrate hydrolysis was 
measured at 412 mn (200 pl final volume) on a microplate reader 
(Thermomax, Molecular Devices). 
Kinetic parameters were determined and commercial cathepsin G 
(ICN Biochemicals) titrated as renorted above. ’ 
The synthetic peptide R13K (RKSIRIQRGPGRK), corresponding 
to fragment 309-320 of the V3 loop sequence of HIV-l Lai was synthe- 
sized and puriiied [13]. Its inhibitory properties were assessed by incu- 
bation with U-937 proteinase or commercial cathepsin G (9 nM final 
concentrations) for 15 min at 25°C and measurement of the remaining 
activity as reported above. 
2.3. Amino-terminal sequence 
Purified proteinase (Superose 12) was reduced, pyridylethylated and 
fractionated by reverse-phase chromatography on a C4 cartridge using 
an isopropanol gradient (O-85%) in 0.1% formic acid. Eluted material 
was concentrated on a ProSpin membrane (Applied Biosystems) which 
was washed three times in 20% methanol. About 100 pmol of sample 
was used for N-terminal sequencing in an Applied Biosystems 477A 
protein sequencer. Phenylthiohydantoin derivatives were identifled on 
an on-line associated ABI 120A analyser [25]. 
2.4. Deglycosylation by en&-P-N-acetyl glucosatninidase F 
Puritied proteinase from U-937 membranes and commercial cathep- 
sin G were deglycosylated using endo-/&Wacetyl glucosaminidase F 
(end0-F; Boehringer) at a maximal concentration of 2 U/mg protein. 
Mixtures were incubated overnight at 30°C in 50 mM potassium phos- 
phate, pH 7.4, 25 mM EDTA, 0.5% Triton X-100, 0.2% SDS, 1% 
2-mercaptoethanol, and analysed by SDS gel-electrophoresis and im- 
munoblotting using the PhastSystem (Pharmacia). 
2.5. Immunoassays 
2.51. Immunoblotting. SDS-PAGE (12.5%) was performed using 
the PhastSystem (Pharmacia) by the procedure of Laemmli [26]. Pro- 
teins were transferred to nitrocellulose (0.45pm; Sartorius) by semi-dry 
electrotransfer for 15 min at 25 mA/20 V The nitrocelhtlose sheet was 
blocked with NaCl/P, (10 mM phosphate, pH 7.4, 150 mM NaQ) 
containing 5% dried milk (w/v) at 37°C for 120 min and treated as 
described elsewhere [271. Anticathepsin G antibodies (ICN Biochemi- 
cals) (diluted 11500 in NaCI/P,, 0.1% Tween 20, 5% dried milk) were 
added and incubated for 18 h at 4°C. The membrane was then washed 
three times with NaCl/‘Pi containing 0.05% Tween 20 and incubated 
with anti-sheep IgG-peroxidase conjugate (Sigma) (diluted l/500 in 
NaCl/Pi, 0.05% Tween 20, 1% dried milk) for 2 h at room temperature 
and washed as before. Antigen was detected by chemiltiescence 
(ECL, Amersham) according to the manufacturer’s instructions. 
2.5.2. Antibody bind&g assay (ELISA test). Microtitration plates 
(Maxisorp; Nunc) were coated with 100 ~1 of commercial cathepsin G 
(ICN Biochemicals), trypsin (Boehringer), kallikrein (rK10, a generous 
gift of Dr. N. Gutman) or membrane-associated serine proteinase from 
U-937 (0.5 mg/ml 0.1 M Tris-HCl buffer, pH 8.2, overnight at 37’C. 
The plates were washed once with NaCl&, 0.1% Tween 20, and satu- 
rated with NaCVP, 10% dried milk for 30 min at 37°C (200 @well). 
Anti-cathepsin G antibodies (diluted l/500 in NaCVP, containing 2.5% 
dried milk) were added and incubated for 1 h at 37’C. Plates were then 
washed three times with NaCl/P,, 0.1% Tween 20, and 100 ~1 of perox- 
idase-conjugated donkey anti-sheep IgG (Sigma) (diluted l/1,000) were 
added to each well and incubated for 1 h at 37°C. Plates were washed 
again, and wells were filled with 100 ,ul ABTS containing 0.03% H,O, 
in 0.1 M citrate-sodium phosphate buffer, pH 4.5, and incubated for 
15 min in the dark. Absorbance was read at 405 mn (Thermomax 
Molecular Devices). 
2.5.3. Fluorescence analysis. U937 cells were washed in PBS, 3% 
foetal calf serum, and labeled with anti-cathepsin G (Mab 1054; 
Euromedex) or anti-CD4 (OKT4.A: Ortho-Diaanostics Svstems) mon- 
oclonal antibodies. Upon‘ incubation and was&g, antibody binding 
was evaluated by flow cytometry (Fats-star; Becton-Dickinson) after 
incubation with FITC-conjugated anti-mouse Ig antibodies (Becton- 
Dickinson). 
3. Results 
The early steps of the purification procedure previ- 
ously used to isolate a serine proteinase interacting with 
HIV- 1 gp 120 and peptides of the V3 loop from the mem- 
brane fraction of U-937 cells were modified as described 
in section 2. The main change was in the preparation of 
the membrane extract, which resulted in a ten-fold in- 
crease in material with serine proteinase activity. This 
activity was fractionated on immobilized benzamidine 
which retained the minor amount of serine proteinase 
activity inhibited by peptides of the V3 loop of HIV 1 
under the chosen experimental conditions.‘This material 
was chromatographed on hydroxyapatite and Superose 
12 [ 131 yielding about 220 pg of serine proteinase from 
2.10” cells, instead of the 20 ,ug previously reported. 
In addition to its trypsin-like activity indicated by hy- 
drolysis of Z-Lys-SBzl, the protease purified by Superose 
12 had a chymotrypsin-like specificity revealed by the 
hydrolysis of Sue-Ala-Ala-Pro-Phe-SBzl. Both of these 
activities were inhibited by STI. Any possibility that a 
multicatalytic proteinase was responsible for this dual 
activity was eliminated by adding Z-Lys-SBzl to the en- 
zyme assayed, with a sutlicient amount of Suc-Ala-Ala- 
Pro-Phe-SBzl to reach the maximal velocity (7 J&J, and 
the residual activity was measured. No increase in en- 
zymic activity was recorded after adding the second sub- 
strate, indicating that the proteinase has one active site 
with both trypsin and chymotrypsin-like specificities. 
The same active site concentration was also found upon 
titration with STI, using either the trypsin- or the chy- 
motrypsin-sensitive substrate (Fig. 1). The specificity 
constants (kat, K,,,) were also determined for each sub- 
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Fig. 1. Titration of the membrane-associated U-937 protease active site. 
Purified proteinase (5 ~1) was incubated for 15 min at 25°C with in- 
creasing amounts of ST1 (O-l .2.10-* M final concentration) before 
adding Z-Lys-SBzl or Sue-Ala-Ala-Pro-Phe-SBzl (0.37 mM final). 
AmAbs,,, was recorded for 5 min. 
strate; the results show similar specificities for trypsin- 
and chymotrypsin-like cleavage sites (Table 1). 
In keeping with these results a single sequence was 
found upon N-terminal sequencing of the ptied mate- 
rial. This experiment was carried out after reverse-phase 
chromatography of 100 pmol protease on a C4 column 
eluted with H,O/isopropanol/formic acid solution to re- 
move the high salt content necessary to preserve the 
proteinase activity. The first 32 N-terminal residues were 
unambiguously identified (Fig. 2). This sequence was 
compared to the most similar sequences found in the 
MIPS data bank (Martinsried Institut for Protein Se- 
quence) using the FASTA program [28]. It is the same 
as that of human cathepsin G [29] except at position 12 
83 
where a Val residue was found in addition to the Arg 
residue present in the cathepsin G sequence (Fig. 2). 
The homology of the U-937 membrane proteinase 
with cathepsin G was further investigated by measuring 
the activity of commercial cathepsin G from human leu- 
kocytes towards thiobenzylester substrates, and its sus- 
ceptibility to inhibitors such as benzamidine, ST1 and the 
synthetic peptide R13K, which spans the V3 loop se- 
quence and includes the conserved GPGR sequence [ 131. 
Both proteinases were inhibited in a similar manner by 
all three inhibitors (Table 2). The peculiar behaviour of 
the U-937 membrane proteinase, which is abnormally 
retained on the Superose 12 column (M, app, < 8 kDa) 
also occurred with leukocyte cathepsin G, as reported by 
others [30]. 
Both proteinases had similar antigenicity when ana- 
lyzed by immuno-blotting (Fig. 3) and ELISA with anti- 
human cathepsin G antibodies. However, the Mrapp, of 
commercial cathepsin G from human leukocytes and 
that of U-937 membranes were slightly different (Fig. 3). 
This difference was not apparent after endoglycosidase 
F treatment, demonstrating that the two enzymes are 
differently glycosylated. A sugar-dependent heterogene- 
ity of cathepsin G has already been reported by Watorek 
et al. [31]. 
The existence of a cathepsin G-related protein in U- 
937 was explored using a cDNA library constructed 
from poly(A)‘ RNA in ngtl 1. This library was screened 
by PCR using two oligonucleotide pairs, taking into ac- 
count the possible valyl residue at position 12. The first 
pair consisted of a sense 23mer (8 l-l 03) CGGGAGAG- 
CAGGCCCCACTCCGT and an antisense 21mer (620- 
600) GGGGCCTCCGGAATCCCCCTT, oligonucleo- 
tides corresponding to the conserved KGDSGGP 
sequence of serine proteinase. The second pair consisted 
of degenerate oligonucleotides corresponding to the 90- 
103 and the 616603 sequences of cathepsin G [29]. PCR 
were carried out using Vent polymerase or its mutant 
deprived of exonucleotidase activity. Amplified frag- 
ments were cloned in pUC19 and double-strand sequenc- 
ing was performed according to Sanger using a Se- 
quenase kit (USB) [32]. All sequences were identical to 
that published for cathepsin G. No evidence was thus 
found for the presence of an enzyme similar to, but dis- 
tinct from, cathepsin G in U-937. The presence of 
Table 1 
Kinetics parameters for hydrolysis of Z-Lys-SBzl and Sue-Ala-Ala-Pro-Phe-SBzl by the membrane-associated cathepsin G-like proteinase of U-937 
cells and by human leukocyte cathepsin G 
Substrate Membrane U-937 cathepsin G-like Human leukocyte cathepsin G 
Kn 
:Ms-‘) 
k 
(mW (?, 
k&G 
$h4) &id) 
k k,,lx, 
(mM_’ . s-1) (sYi) (mM-’ . s-‘) 
Z-Lys-SBzl 1.15 0.42 46 41 0.76 1.25 16 21 
Sue-Ala-Ala-Pro-Phe-SBzl 0.26 0.16 17 68 0.51 1.15 14 28 
Kinetic constants were calculated from Hanes linear plot using at least seven substrate concentrations. 
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Fig. 2. Amino-terminal sequence of purified membrane-associated U-937 cathepsin G-like protease. About 100 pmol U-937 membrane-associated 
protease was used for N-terminal sequencing. The number of pmol per cycle is indicated below each residue. The first 32 residues were identical to 
those in human leukocyte cathepsin G, except at position 12 where a Val residue was found in addition to the Arg residue present in the cathepsin 
G sequence. 
cathepsin G-like material at the surface of U-937 mem- 
branes has been further investigated using a monoclonal 
antibody against human leukocyte cathepsin G. Fluores- 
cence analysis indicated that U937 cells could be stained 
by anti-cathepsin G mAbs at a level similar to that with 
anti-CD4 mAbs (Fig. 4). 
ryptic cleavage sites are similar, indicating that the two 
activities might be similarly efficient. The proteinases 
previously reported by Kido et al. [lo] and Murakami et 
al. [ 121 in Molt 4-cells, although distinct from the cathep- 
sin G-related proteinase from U-937 cells, also have dual 
specificity. This is not the case, however, for dipeptidyl 
peptidase IV, which has a restricted specificity and is not 
inhibited by peptides of the V3 loop of gp120 [14]. 
4. Discussion 
The proteinase we have purified and examined in this 
study is present at the surface of U-937 cells, from which 
it can be released by high salt treatment and sonication. 
This proteinase is strongly inhibited by recombinant 
gp120 by interaction with its V3 loop, and this interac- 
tion can lead to cleavage of the peptide chain [l&16]. 
Such a cleavage could induce a conformational change 
of gp120 required for subsequent virus internalization 
[33,34]. If so, the specificity of the enzyme should be wide 
enough to allow interaction or infection by HIV-l and 
possibly HIV-2 strains that may infect monocytic cell 
lines. Cleavage sites of trypsin-, chymotrypsin- or aspar- 
tic acid-like specificity have been demonstrated at the tip 
of the V3 loop of all infectious HIV-l, HIV-2 and SIV 
isolates [8-l 1,16,35]. It has therefore been suggested that 
one multispecihc proteinase or several proteinase are 
required to ensure cleavage of the V3 loop in all HIV 
strains [ 151. We have demonstrated that the enzyme from 
U-937 cell membrane is specific for both trypsin- and 
chymotrypsin-like cleavage sites, which fits with the re- 
quirement for a multispecific proteinase. Moreover, the 
specificity constants (kcat, K,J for the tryptic and chymot- 
The amino acid sequence of the first 32 N-terminal 
residues of the purified proteinase was the same as that 
of human leukocyte cathepsin G, which agrees with the 
chymotrypsin-like specificity of this proteinase. How- 
ever, there has been no report, so far, describing a tryp- 
sin-like specificity for cathepsin G except for the cleavage 
of an Arg-Ser bond in the C3 component of complement 
[36]. This study showes that commercial leukocyte 
cathepsin G hydrolyses Z-Lys-SBzl as well as Suc-Ala- 
Ala-Pro-Phe-SBzl. Commercial cathepsin G also has the 
same sensitivity and specificity towards inhibitors, in- 
cluding the V3 loop peptide R13K, and has physico- 
chemical properties similar to those of the U-937 
enzyme. Both enzymes also share common antigenic 
properties. 
Although initially described in the granules of poly- 
morphonuclear leukocytes (neutrophils), cathepsin G 
has also been identified in U-937 promonocytic cells 
[29,36,37]. Its biological function is still far from clear 
and little is known about its physiological substrates. 
However, it has been reported to degrade proteoglycans 
efficiently [31] and generate angiotensin 2 from angioten- 
sin 1 [38]. More recently a small fraction of U-937 
cathepsin G has been found to be associated with the 
Table 2 
Inhibition of U-937 membrane-associated cathepsin G-like proteinase and leukocyte cathepsin G 
Inhibitor Proteinase EII Inhibition (96) 
Z-Lys-SBzl 
(0.37 mM) 
Sue-Ala-Ala-Pro-Phe-SBzl 
(0.37 mM) 
ST1 (17 nM) 
Benzamidine (2 mM) 
R13K (60 PM) 
U-937 Mb. cathepsin G-like 
Leukocyte cathepsin G 
U-937 Mb. cathepsin G-like 
Leukocyte cathepsin G 
U-937 Mb. cathepsin G-like 
Leukocyte cathepsin G 
9nM 0.5 82 86 
9nM 0.5 77 78 
9nM 4.5.10+ 24 24 
9nM 4.5 1o-6 14 26 
9nM 1.5.10-4 75 78 
9nM 1.5.10-4 70 66 
Membrane-associated cathepsin G-like proteinase from U-937 cells and cathepsin G from human leukocytes (9 nM tinal) were incubated with inhibitor 
solutions for 15 min at 25°C in 200 ,ul of 0.10 M Tris-HCl buffer, pH 8.2, containing 0.35 mM 5,5’-dithiobis (nitrobenzoic acid). The reaction was 
started with 5 ~1 of substrate (Z-Lys-SBzl or Sue-Ala-Ala-Pro-Phe-SBzl, 0.37 mM final). The absorbance at 412 mn was recorded for 5 min. 
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Fig. 3. Immunoblotting of puritied membrane-associated U-937 
cathepsin G-like protease and leucocyte cathepsin G with anticathep- 
sin G antibodies. Samples (about 20 ng) of membrane-associated U-937 
cathepsin G were electro-immunoblotted after SDS-PAGE without (A) 
and with (B) prior reduction, and before (E) and after (F) deglycosyla- 
tion. Commercial cathepsin G from human leukocytes is shown for 
comparison, prior to (C) and after (D) deglycosylation. 
plasma membrane, to participate in the generation of 
active fragments from the C3 component of complement, 
and in the inactivation of interleukin 6 together with a 
peptidyl-transfering enzyme [36,39]. We used a monoclo- 
nal antibody directed against human cathepsin G to con- 
firm that the proteinase is present at the surface of U-937 
cells. The location of the proteinase at the surface of the 
plasma membrane, together with its dual specificity for 
trypsin and chymotrypsin sites, make it a good candidate 
to participate in the entry of HIV into these cells should 
a proteinase be required. However, cathepsin G has not 
been found in other cells that are sensitive to HIV-l 
infection, suggesting that other proteinases or cofactors 
in such cells should be involved in the interaction with 
the V3 loop [2,3,15]. We are now examining the interac- 
tion between U-937 membrane cathepsin G and syn- 
thetic peptides mimicking the crown of the V3 loop of 
HIV strains with different tropism for T lymphocytes or 
monocytes. Transfection of cathepsin G into cells non- 
permissive to HIV will also provide further evaluation of 
the role of this proteinase in HIV infection 
log rclalivc Iluorcsccncc inlcnsily 
Fig. 4. Indirect fluorescence analysis of cathepsin G expression at the 
surface of U-937 cells. Fluorescence intensity is shown after cell la- 
belling with anti-human cathepsin G (A) and anti-CD4 (B). Peak (C) 
denotes the fluorescence of the FITC labelled second antibody. 
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